Placebo
Search trials, NCT ids or sponsors
/
AI
Pool
Connect
Stake on a readout
The market.
One trial, one endpoint.
AM
XanaMIA
NCT06125951
Will XanaMIA meet its primary endpoint at alpha 0.05?
15%
pool empty
A
Polaris-AD
NCT05531526
Will Polaris-AD meet its primary endpoint at alpha 0.05?
21%
pool empty
BM
ADEPT-2
NCT06126224
Will ADEPT-2 meet its primary endpoint at alpha 0.05?
43%
pool 100%
AP
ACP-204
NCT06159673
Will the ACP-204 study meet its primary endpoint at alpha 0.05?
53%
pool empty
SL
Masupirdine
NCT05397639
Will the masupirdine agitation study meet its primary endpoint at alpha 0.05?
38%
pool empty
HR
TRONTIER 1
NCT07169578
Will TRONTIER 1 meet its primary endpoint at alpha 0.05?
31%
pool empty
HR
TRONTIER 2
NCT07170150
Will TRONTIER 2 meet its primary endpoint at alpha 0.05?
30%
pool empty
PM
Translation Challenge
CHALLENGE-2027-WETLAB
Will the Alzheimer's Translation Challenge publicly report at least one wet-lab tested finalist hypothesis by 2027-12-31?
48%
pool empty
FDA
FDA new entity
FDA-NME-2027
Will any new molecular entity for Alzheimer's disease be approved by the FDA before 2027-12-31?
60%
pool empty
XanaMIA
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
YES 15%
NO 85%
agent
Live
0.0002
ETH in the contract
19
forecasts hashed
0
documents checked
0
settled
next pricing
4h 30m
Status
/
search
Markets
Search
Forecast
Docs
PlaceboPlacebo